About eTheRNA

Engineering the Future of mRNA

eTheRNA immunotherapies is driving mRNA technology and therapeutic product development to deliver an innovative generation of RNA chemistries, RNA process technologies and a new and advanced generation of therapeutic and vaccine products. eTheRNA uses its established R&D foundations and in-house GMP manufacturing facilities and builds on its proprietary mRNA, mRNA adjuvant and mRNA formulation platforms to progress technology innovation and product development.

eTheRNA was established in January 2013 as a spin-off company from the ‘Vrije Universiteit Brussel’ (VUB), following the development of its TriMix mRNA technology.

// OUR COMPANY

What We Do

eTheRNA’s goal is to commercialize mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases.

LEARN MORE

Immunotherapies

eTheRNA builds on more than 30 years of research grade mRNA manufacturing, and more than 5 years of GMP mRNA production.

LEARN MORE

Contract Manufacturing

// Stay up to date

Newsroom

// 22 September 2021

eTheRNA immunotherapies conference attendance from September to October 2021

Niel (Belgium)

eTheRNA immunotherapies NV (‘eTheRNA’), a private clinical-stage biotechnology company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, will be attending the following conferences from September through to October 2021:

Discover all news articles